- Published: May 2012
- Region: Global
Global Genitourinary Drugs Market 2011-2015
- ID: 2304307
- October 2012
- Region: Global
- 71 pages
TechNavio's analysts forecast the Global Genitourinary Drugs market to grow at a CAGR of 3.05 percent over the period 2011-2015. One of the key factors contributing to this market growth is the entry of novel biological drugs. The Global Genitourinary Drugs market has also been witnessing a paradigm shift toward biological drugs. However, lack of adherence to medication could pose a challenge to the growth of this market.
TechNavio's report, the Global Genitourinary Drugs Market 2011-2015, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Genitourinary Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this space are Abbott Laboratories, Astellas Pharma Inc., Bayer AG, Eli Lilly and Co., GlaxoSmithKline plc, Merck and Co. Inc., and Pfizer Inc.
Other vendors mentioned in the report are Agile Therapeutics Inc., Allergan Inc., Antares Pharma Inc., Boehringer Ingelheim GmbH, Dong-A Pharmaceutical Co. Ltd., Detrol LA, Ferring Holding S.A., Kissei Pharmaceutical Co. Ltd., Merck Serono S.A., Novartis International AG, Novo Nordisk A/S, Nymox Pharmaceutical Corp., PregLem S.A., Recordati S.p.A., Rottapharm S.p.A., Teva Pharmaceutical Industries Ltd., VIVUS Inc., Warner Chilcott plc, and Watson Pharmaceuticals Inc.
Key questions answered in this report:
What will the market size be in 2015 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of analyst time when you purchase this report. Details provided within the report.
TechNavio's research portfolio in the Healthcare series includes reports on the Pharmaceutical Market, Medical Devices Market, Diagnostic Market, Vaccine Market, Oncology Market, CRO Market, Orthopedic Market, Hearing Aids Market, Dental Care Market, Medical Imaging Market, Endoscopy Market, Dialysis Market, Telemedicine Market, Cancer Drug Market, Glucose Monitoring Market, Infusion Pumps Market, Defibrillators Market, Neuromodulation Market, Capnography Market. SHOW LESS READ MORE >
01. Executive Summary
03. Market Coverage
04. Market Landscape
04.1 Global Genitourinary Drugs Market
04.2 Genitourinary Drugs Market in the US
04.3 Genitourinary Drugs Market in Japan
04.4 Key Market Segmentation
04.5 Five Forces Analysis
05. Geographical Segmentation
06. Key Leading Countries
07. Vendor Landscape
08. Buying Criteria
09. Market Growth Drivers
10. Drivers and their Impact
11. Market Challenges
12. Impact of Drivers and Challenges
13. Market Trends
14. Key Vendor Analysis
14.1 Pfizer Inc.
14.2 Bayer AG
14.3 Eli Lilly and Co.
14.4 Merck and Co. Inc.
14.5 Astellas Pharma Inc.
14.6 GlaxoSmithKline plc
14.7 Abbott Laboratories
15. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Genitourinary Drugs Market 2011-2015 (US$ billion)
Exhibit 2: Genitourinary Drugs Market in the US 2011-2015 (US$ billion)
Exhibit 3: Genitourinary Drugs Market in Japan 2011-2015 (US$ billion)
Exhibit 4: Global Genitourinary Drugs Market by Application Segmentation
Exhibit 5: Global Genitourinary Drugs Market by Application Segmentation 2011
Exhibit 6: Genitourinary Drugs Market by Application Segmentation 2015
Exhibit 7: Comparison of Global Genitourinary Drugs Market by Application Segmentation 2011 versus 2015 (percentage)
Exhibit 8: Global Hormonal Contraception Drugs Market 2011-2015 (US$ billion)
Exhibit 9: Global Benign Prostatic Hyperplasia Drugs Market 2011-2015 (US$ billion)
Exhibit 10: Global Erectile Dysfunction Drugs Market 2011-2015 (US$ billion)
Exhibit 11: Global Urinary Incontinence Drugs Market 2011-2015 (US$ billion)
Exhibit 12: Global Infertility Drugs Market 2011-2015 (US$ billion)
Exhibit 13: Global Infection Drugs Market 2011-2015 (US$ billion)
Exhibit 14: Global Genitourinary Drugs Market by Geographical Segmentation 2011
Exhibit 15: Global Genitourinary Drugs Market by Vendor Segmentation 2011
Exhibit 16: Global Genitourinary Drugs Market by Vendor Segmentation 2015
Exhibit 17: Business Segmentation of Pfizer Inc.
Exhibit 18: Business Segmentation of Bayer AG
Exhibit 19: Business Segmentation of Eli Lilly and Co.
Exhibit 20: Business Segmentation of Merck and Co. Inc.
Exhibit 21: Business Segmentation of Astellas Pharma Inc.
Exhibit 22: Business Segmentation of GlaxoSmithKline plc
Exhibit 23: Business Segmentation of Abbott Laboratories
TechNavio Announces the Publication of its Research Report - Global Genitourinary Drugs Market 2011-2015
TechNavio today launched its report, Global Genitourinary Drugs Market 2011-2015, based on an in-depth analysis covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers' understanding of the present and future landscape of the market.
Commenting on the report, an analyst from TechNavio's Healthcare team said: ''Patients suffering from infections and disorders related to genitourinary systems are using steroids and immunosuppressants. However, these medications cause serious side effects because they are chemically synthesized. Hence, patients are turning to biological drugs that not only cause fewer side effects, but are also more effective in the treatment of genitourinary infection. Moreover, there has been an increase in the number of biological drugs entering the Global Genitourinary Drugs market.''
According to the report, one of the major growth factors driving the Global Genitourinary Drugs market is the entry of novel drugs such as Cialis which are more effective than the drugs used in multiple-drug therapies. These novel drugs provide cost-effective treatment for genitourinary infection.
Further, the report reveals that one of the major challenges is the increase in the patent expiries of the best-selling drugs in the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.